NCT02447367 is a Phase 1 clinical trial of JLP-1207(Fasted) in LUTS, sponsored by Jeil Pharmaceutical Co., Ltd..

Who is sponsoring NCT02447367?

NCT02447367 is sponsored by Jeil Pharmaceutical Co., Ltd..

What drugs are being tested in NCT02447367?

Interventions in NCT02447367: JLP-1207(Fasted), JLP-1207(Fed).

What condition does NCT02447367 study?

NCT02447367 studies LUTS, Benign Prostatic Hyperplasia, Overactive Bladder.

Is NCT02447367 still recruiting?

NCT02447367 is currently completed. Last updated 23 June 2016.

Last reviewed 2016-06-23 · How we verify

NCT02447367

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized, Open-label, Single Dose, Two-way Crossover, Clinical Trial to Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 After Oral Administration in Healthy Male Volunteers

Completed Phase 1 Last updated 23 June 2016

What this trial tests

Phase 1 trial testing JLP-1207(Fasted) in LUTS in 54 participants. Completed in 1 December 2015.

Timeline

1 July 2015

Primary endpoint
1 September 2015

1 December 2015

Quick facts

Lead sponsor	Jeil Pharmaceutical Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	1 July 2015
Primary completion	1 September 2015
Estimated completion	1 December 2015

Drugs / interventions tested

JLP-1207(Fasted) — full drug profile →
JLP-1207(Fed) — full drug profile →

Conditions studied

LUTS — all drugs for LUTS →
Benign Prostatic Hyperplasia — all drugs for Benign Prostatic Hyperplasia →
Overactive Bladder — all drugs for Overactive Bladder →

Sponsor

Jeil Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 19 to 45, male only, with LUTS or Benign Prostatic Hyperplasia. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

AUClast, Cmax, AUCinf
Time frame: 192 hours

Sponsor's own description

The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Jeil Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07115706 — JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD · not yet recruiting
NCT06952855 — Observationa Study is a Prospective and Multi-institutional Observational Study. · completed
NCT06431399 — To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004 · Phase 1 · recruiting
NCT06169059 — To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004 · Phase 1 · completed
NCT06165965 — To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02447367 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jeil Pharmaceutical Co., Ltd.
Last refreshed: 23 June 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02447367.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing